165 related articles for article (PubMed ID: 25844352)
1. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer.
Cho JS; Park MH; Ryu YJ; Yoon JH
Ann Surg Treat Res; 2015 Apr; 88(4):187-92. PubMed ID: 25844352
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer.
Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI
Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte Ratio Is Associated With the Proportion of Poorly Differentiated Components in Papillary Thyroid Carcinoma.
Oba T; Maeno K; Kiyosawa N; Morikawa H; Amitani M; Chino T; Shimizu T; Ono M; Ito T; Kanai T; Uehara T; Ito KI
J Surg Res; 2023 Jul; 287():47-54. PubMed ID: 36868123
[TBL] [Abstract][Full Text] [Related]
4. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
[TBL] [Abstract][Full Text] [Related]
5. The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid Cancer Patients on Tyrosine Kinase Inhibitor Therapy.
Tomoda C; Sugino K; Kitagawa W; Nagahama M; Ito K
ORL J Otorhinolaryngol Relat Spec; 2021; 83(5):347-353. PubMed ID: 33735904
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
[TBL] [Abstract][Full Text] [Related]
7. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
8. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
Romei C; Tacito A; Molinaro E; Piaggi P; Cappagli V; Pieruzzi L; Matrone A; Viola D; Agate L; Torregrossa L; Ugolini C; Basolo F; De Napoli L; Curcio M; Ciampi R; Materazzi G; Vitti P; Elisei R
Oncol Lett; 2018 Jun; 15(6):9174-9182. PubMed ID: 29805648
[TBL] [Abstract][Full Text] [Related]
9. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
10. MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer.
Zhou J; Xu M; Tan J; Zhou L; Dong F; Huang T
Front Oncol; 2022; 12():1030590. PubMed ID: 36479070
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma.
Yamazaki H; Sugino K; Matsuzu K; Masaki C; Akaishi J; Hames K; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Masuda M; Ito K
Endocrine; 2020 Oct; 70(1):115-122. PubMed ID: 32307657
[TBL] [Abstract][Full Text] [Related]
12. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.
Ryder M; Ghossein RA; Ricarte-Filho JC; Knauf JA; Fagin JA
Endocr Relat Cancer; 2008 Dec; 15(4):1069-74. PubMed ID: 18719091
[TBL] [Abstract][Full Text] [Related]
13. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
[TBL] [Abstract][Full Text] [Related]
14. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Choi HS; Park do J; Jung KC; Sung MW; Kim KH; Hah JH; Park YJ
Thyroid; 2016 Sep; 26(9):1259-68. PubMed ID: 27412715
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated and anaplastic thyroid cancer.
Patel KN; Shaha AR
Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
[TBL] [Abstract][Full Text] [Related]
16. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
17. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?
Wen D; Hu JQ; Wei WJ; Ma B; Lu ZW; Wang YL; Wang Y; Ji QH
Int J Clin Exp Pathol; 2019; 12(1):267-274. PubMed ID: 31933742
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio.
Xu B; Zhang L; Setoodeh R; Mohanty AS; Landa I; Balzer B; Tiedje V; Ganly I; Dogan S; Fagin JA; Ghossein R
Endocrine; 2022 Jun; 76(3):612-619. PubMed ID: 35149932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
